Skip to main content
Premium Trial:

Request an Annual Quote

BGI Gets CE-IVD Mark for Thalassemia Test

NEW YORK — BGI Genomics said on Thursday that it has received CE-IVD marking for its next-generation sequencing-based test for thalassemia mutation detection.

The Thalassemia Gene Detection Kit (Combinatorial Probe-Anchor Synthesis Sequencing Method) qualitatively detects the mutations that cause alpha- and beta-thalassemia, two heritable disorders characterized by low hemoglobin levels. The test is designed for screening the general population, as well as to diagnose patients carrying the mutations and experiencing abnormal hemoglobinopathy, the company said.

"Screening for thalassemia through genetic testing is vital so that carriers and at-risk couples may be informed about their risk and the options for reducing it," Jingjing Xiao, senior product manager at BGI Genomics, said in a statement.

BGI Genomics is the clinical genetic testing and research services arm of China's BGI Group.

The Scan

Open Pediatric Brain Tumor Atlas Team Introduces Genomic Data Collection, Analytical Tools

A study in Cell Genomics outlines open-source methods being used to analyze and translate whole-genome, exome, and RNA sequence data from the Pediatric Brain Tumor Atlas.

Neurological Outcomes Linked to Innate Immune Features After Cardiac Arrest

Researchers reporting in Med dig into immune features found a few hours after cardiac arrest that correspond with neurological outcomes.

Mouse Study Finds Circadian Rhythm-Related Gene Expression Changes Linked to Sleep Apnea

A paper in PLOS Biology reveals tissue-specific circadian rhythm and gene expression patterns in an intermittent hypoxia-based mouse model of obstructive sleep apnea.

Polygenic Risk Score to Predict Preeclampsia, Gestational Hypertension in Pregnant Women

Researchers in Nature Medicine provide new mechanistic insights into the development of hypertensive disorders of pregnancy, which may help develop therapeutics.